Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437401 | 0.91 | KMT2A (0.50) | KMT2AMEN1LMNACYP1A2ALDH1A1 | |
| SCHEMBL932927 | 0.84 | KMT2A (0.45) | KMT2AMEN1CYP3A4LMNAMAOA | |
| SCHEMBL143772 | 0.84 | MEN1 (0.61) | KMT2AMEN1LMNAALDH1A1L3MBTL1 | |
| SCHEMBL23533686 | 0.83 | TAAR1 (0.54) | KMT2ALMNACYP1A2ALDH1A1TDP1 | |
| SCHEMBL1934595 | 0.83 | KMT2A (0.44) | KMT2AMEN1LMNAALDH1A1TDP1 | |
| SCHEMBL5709288 | 0.83 | TPSAB1 (0.51) | KMT2AMEN1ALDH1A1MAOBPARP10 | |
| SCHEMBL25448604 | 0.83 | KMT2A (0.44) | KMT2AMEN1CYP3A4LMNAMAOA | |
| SCHEMBL1561073 | 0.83 | ALDH1A1 (0.45) | KMT2AMEN1CYP3A4LMNAMAOA | |
| SCHEMBL17080518 | 0.81 | CYP3A4 (0.54) | KMT2AMEN1CYP3A4PARP10APP | |
| SCHEMBL2511445 | 0.81 | ALDH1A1 (0.64) | KMT2AMEN1CYP3A4LMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055169-A | Anti-PSMA antibody drug conjugates comprising irinotecan | ADC疗法责任有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | claimed |
| US-20260061066-A1 | ANTI-GRP78 ANTIBODY, IMMUNOCONJUGATE AND USES THEREOF | UCT BIOSCIENCE CO., LTD. (TW) | 2026-03-05 | — | — | US | claimed |
| US-20260027241-A1 | Near-Infrared Dyes And Conjugates For Targeting Tumors | LAHJAVIDA, INC. (US) | 2026-01-29 | — | — | US | claimed |
| US-20260021191-A1 | TUMOR MICROENVIRONMENT-ACTIVATED CYTOKINE AND USE THEREOF | YAFEI SHANGHAI BIOLOGY MEDICINE SCIENCE & TECH CO LTD (CN) | 2026-01-22 | — | — | US | claimed |
| EP-4680644-A1 | SACITUZUMAB DRUG CONJUGATES AND PREPARATION THEREOF | Zydus Lifesciences Limited (IN) | 2026-01-21 | — | — | EP | claimed |
| EP-4665770-A1 | DARATUMUMAB DRUG CONJUGATES AND PREPARATION THEREOF | Zydus Lifesciences Limited (IN) | 2025-12-24 | — | — | EP | claimed |
| EP-4658690-A2 | ANTI-CD180 BINDING MOLECULES AND USES THEREOF | Corellia AI (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | claimed |
| EP-4646233-A1 | HER3-BINDING ANTIBODY-DRUG CONJUGATE | Hummingbird Bioscience Pte. Ltd. (SG) | 2025-11-12 | — | — | EP | claimed |
| US-10335501-B2 | Cyclic peptides with enhanced nerve-binding selectively, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-07-02 | — | — | US | claimed |
| US-10287564-B2 | Procoagulant compounds | BIOVERATIV THERAPEUTICS INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-20190070310-A1 | NANOPARTICLE DRUG CONJUGATES | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-03-07 | — | — | US | claimed |
| US-10111963-B2 | Nanoparticle drug conjugates | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-10-30 | — | — | US | claimed |
| US-20160166714-A1 | CYCLIC PEPTIDES WITH ENHANCED NERVE-BINDING SELECTIVELY, NANOPARTICLES BOUND WITH SAID CYCLIC PEPTIDES, AND USE OF SAME FOR REAL-TIME IN VIVO NERVE TISSUE IMAGING | MEMORIAL SLOAN KETTERING CANCER CENTER | 2016-06-16 | — | — | US | claimed |
| US-20150343091-A1 | NANOPARTICLE DRUG CONJUGATES | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-12-03 | — | — | US | claimed |
| US-20150184142-A1 | PROCOAGULANT COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2015-07-02 | — | — | US | claimed |
| EP-2858659-A1 | PROCOAGULANT COMPOUNDS | Biogen Idec MA Inc. (US) | 2015-04-15 | — | — | EP | claimed |
| US-8796229-B2 | Feedback prodrug | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-08-05 | — | — | US | claimed |
| WO-2013185113-A1 | PROCOAGULANT COMPOUNDS | BIOGEN IDEC MA INC. (US) | 2013-12-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | KMT2A 718/4885MEN1 383/4885CYP3A4 1533/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | KMT2A 3488/4885MEN1 35/4885CYP3A4 1802/4885 |
| US-10287564-B2 | Procoagulant compounds | PLG, F2, PLAT | KMT2A 3722/4885MEN1 1483/4885CYP3A4 1524/4885 |
| US-20260021191-A1 | TUMOR MICROENVIRONMENT-ACTIVATED CYTOKINE AND USE THEREOF | IFNG, IFNAR1, STAT1 | KMT2A 2390/4885MEN1 2090/4885CYP3A4 3615/4885 |
| US-20150184142-A1 | PROCOAGULANT COMPOUNDS | PLG, F2, PLAT | KMT2A 3722/4885MEN1 1483/4885CYP3A4 1524/4885 |
| US-20260061066-A1 | ANTI-GRP78 ANTIBODY, IMMUNOCONJUGATE AND USES THEREOF | IGSF11, DNAJC10, HSPA5 | KMT2A 3849/4885MEN1 4354/4885CYP3A4 4803/4885 |
| US-20260027241-A1 | Near-Infrared Dyes And Conjugates For Targeting Tumors | ADAMTS1, ADAMTS4, ADAMTS5 | KMT2A 3222/4885MEN1 2366/4885CYP3A4 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.